Purchase of DPYD (dihydropyrimidine dehydrogenase) testing kits
All Wales Genomics Laboratory (AWMGL) has been providing testing for DPYD (dihydropyrimidine dehydrogenase) deficiency since July 2020. Germline variants in the DPYD gene can confer an increased risk of severe or fatal toxicity for cancer patients being treated with common fluoropyrimidine based chemotherapies, 5-fluoruracil and/or capecitabine. Therefore results allow clinicians to assess if the treatment is suitable for the patient. Due to considerable increase in the demand for the test the AWMGL intends to awar...
Buyer
NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust)
Value
£232,200
Published
16 Jun 2021
Closes
16 Jun 2021
Procurement details
Source
Find a Tender
Region
United Kingdom
Procurement method
Limited
Category
Goods
Contract starts
Not provided
Contract ends
Not provided
CPV classifications
33696500
Laboratory reagents
Lots
Lot 1 Purchase of DPYD (dihydropyrimidine dehydrogenase) testing kits
£232,200
All Wales Genomics Laboratory (AWMGL) has been providing testing for DPYD (dihydropyrimidine dehydrogenase) deficiency since July 2020. Germline variants in the DPYD gene can confer an increased risk of severe or fatal toxicity for cancer patients being treated with common fluoropyrimidine based chemotherapies, 5-fluoruracil and/or capecitabine. Therefore re...
Delivery: Cardiff and Vale of Glamorgan
Documents
No document metadata is available for this public record.
Contains public sector information licensed under the Open Government Licence v3.0.